$86.63
+0.57(0.66%)
Mkt Cap $111.2B
$80.68
$105.35
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Total Reportable Segments (33.6%), Cardiovascular (25%), Neuroscience Group (19.7%).
8-K
Medtronic plc announced Q3 FY26 financial results with $9.017 billion revenue, up 8.7% reported and 6.0% organic, and non-GAAP diluted EPS of $1.36, both ahead of guidance. The company reiterates FY26 organic revenue growth of approximately 5.5% and non-GAAP diluted EPS guidance of $5.62 to $5.66.$111.2B
Market Cap
$35.5B
Revenue
$4.6B
Net Income
Employees95,000
Fundamentals
How The Business Makes Money
Revenue by Segment
Total Reportable Segments33.6%($192.7B)
Cardiovascular25%($143.3B)
Neuroscience Group19.7%($112.8B)
Medical Surgical17.3%($99.3B)
Diabetes Group3.9%($22.5B)
All Other Segments0.3%($1.7B)
Other Segment0.1%($853M)
Revenue by Geography
US34.5%($150.0B)
International32.4%($140.7B)
Total Other Countries Excluding Ireland22.3%($96.8B)
Total Other Countries Excluding United Statesand Ireland10.7%($46.7B)
IE0.1%($327M)
Activity
Company Profile
CIK0001613103
ISINIE00BTN1Y115
CUSIPG5960L103
Phone353 1 438 1700
Address20 On Hatch, Galway, 2, IE
SEC EDGAR